[
  {
    "id": "rwe-cibmtr-axi-001",
    "text_summary": "CIBMTR registry analysis of 1297 patients receiving axicabtagene ciloleucel for relapsed/refractory LBCL in commercial setting (2018-2022). Real-world ORR was 73% with 54% CR, compared to 83% ORR and 58% CR in the ZUMA-1 pivotal trial. Median OS was 19.8 months with a 2-year OS rate of 47%. Patients were older (median 63 years) and had more comorbidities than trial populations, suggesting the efficacy gap is driven by broader patient selection.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "axicabtagene ciloleucel",
    "indication": "LBCL",
    "population_size": 1297,
    "median_followup_months": 24.6,
    "primary_endpoint": "ORR",
    "outcome_value": "73%",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-cibmtr-tisa-002",
    "text_summary": "CIBMTR registry outcomes for tisagenlecleucel in 506 adult DLBCL patients treated commercially. ORR was 62% with 40% CR, compared to 52% ORR and 40% CR in JULIET. Median PFS was 5.9 months. Grade 3+ CRS occurred in 8% and grade 3+ neurotoxicity in 6%, lower than pivotal trial rates. The lower severe toxicity rate in real-world likely reflects improved CRS management and earlier tocilizumab use.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "tisagenlecleucel",
    "indication": "DLBCL",
    "population_size": 506,
    "median_followup_months": 18.3,
    "primary_endpoint": "ORR",
    "outcome_value": "62%",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-cibmtr-liso-003",
    "text_summary": "CIBMTR analysis of 412 patients receiving lisocabtagene maraleucel for relapsed/refractory LBCL. Real-world ORR was 69% with 52% CR, closely matching the TRANSCEND NHL 001 trial results of 73% ORR and 53% CR. Grade 3+ CRS was 3% and grade 3+ ICANS was 8%. The close alignment with pivotal data may reflect the TRANSCEND trial's broader eligibility criteria, which better represented real-world patients.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "lisocabtagene maraleucel",
    "indication": "LBCL",
    "population_size": 412,
    "median_followup_months": 15.7,
    "primary_endpoint": "ORR",
    "outcome_value": "69%",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-cibmtr-ide-004",
    "text_summary": "CIBMTR registry data on 987 patients receiving idecabtagene vicleucel for relapsed/refractory multiple myeloma after 4+ prior lines. Real-world ORR was 71% with 33% CR/sCR, compared to 73% ORR and 33% CR in KarMMa. Median PFS was 8.8 months. Grade 3+ CRS occurred in 5% and grade 3+ neurotoxicity in 4%. Results suggest commercial ide-cel outcomes are concordant with the pivotal trial in multiple myeloma.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "idecabtagene vicleucel",
    "indication": "Multiple Myeloma",
    "population_size": 987,
    "median_followup_months": 14.2,
    "primary_endpoint": "ORR",
    "outcome_value": "71%",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-acad-vs-comm-005",
    "text_summary": "Multi-center retrospective study comparing CAR-T outcomes at 12 high-volume academic centers (>50 infusions/year) vs 24 community-based certified centers. Academic centers had higher CR rates (57% vs 44%, p=0.003) and lower 100-day NRM (3.1% vs 5.8%, p=0.02). ICU transfer rates were 28% at academic vs 39% at community sites. The volume-outcome relationship suggests a minimum of 20-25 infusions per year for optimal outcomes.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 834,
    "median_followup_months": 12.4,
    "primary_endpoint": "CR rate",
    "outcome_value": "57% academic vs 44% community",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-community-exp-006",
    "text_summary": "Analysis of 193 patients treated at community oncology centers newly certified for CAR-T administration. Early experience (first 10 patients) showed higher grade 3+ CRS (18%) vs later experience (8%, p=0.04). 30-day mortality decreased from 6.2% to 2.1% as institutional experience grew. Time from leukapheresis to infusion was longer at community sites (median 35 vs 28 days at academic centers), reflecting coordination challenges with manufacturing logistics.",
    "study_type": "retrospective",
    "data_source": "institutional",
    "product": "axicabtagene ciloleucel",
    "indication": "LBCL",
    "population_size": 193,
    "median_followup_months": 10.8,
    "primary_endpoint": "NRM",
    "outcome_value": "3.6% overall 30-day mortality",
    "setting": "community",
    "special_population": ""
  },
  {
    "id": "rwe-acad-higvol-007",
    "text_summary": "Single high-volume academic center experience with 387 consecutive CAR-T infusions across all products (2018-2023). Center achieved 76% ORR, 56% CR for LBCL indications. Standardized CRS management protocol with early tocilizumab (within 12 hours of grade 2) reduced ICU transfers from 35% to 18% over the study period. Dedicated CAR-T coordinators reduced median time from referral to infusion from 52 to 38 days.",
    "study_type": "retrospective",
    "data_source": "institutional",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 387,
    "median_followup_months": 20.1,
    "primary_endpoint": "ORR",
    "outcome_value": "76%",
    "setting": "academic",
    "special_population": ""
  },
  {
    "id": "rwe-elderly-safety-008",
    "text_summary": "Retrospective analysis of 348 patients aged 65 years or older receiving commercial CAR-T for LBCL across 15 US centers. ORR was 68% with 48% CR, not significantly different from younger patients (72% ORR, 53% CR, p=0.14). However, grade 3+ CRS was higher in elderly (15% vs 9%, p=0.01) and ICU admission was 38% vs 25%. Non-relapse mortality at 1 year was 8.2% in elderly vs 4.1% in younger patients. Baseline comorbidity index was a stronger predictor than age alone.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 348,
    "median_followup_months": 16.5,
    "primary_endpoint": "ORR",
    "outcome_value": "68%",
    "setting": "both",
    "special_population": "elderly ≥65"
  },
  {
    "id": "rwe-elderly-mm-009",
    "text_summary": "Analysis of 214 multiple myeloma patients aged 65-80 receiving idecabtagene vicleucel or ciltacabtagene autoleucel. ORR was 69% with 30% sCR. Patients aged 70-80 had higher grade 3+ CRS (12% vs 6%) and prolonged cytopenias lasting >60 days (41% vs 24%) compared to 65-69 year olds. Median PFS was 9.1 months for the full cohort. Baseline frailty assessment correlated with toxicity risk better than chronological age.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "Multiple Myeloma",
    "population_size": 214,
    "median_followup_months": 12.8,
    "primary_endpoint": "ORR",
    "outcome_value": "69%",
    "setting": "academic",
    "special_population": "elderly ≥65"
  },
  {
    "id": "rwe-elderly-ball-010",
    "text_summary": "CIBMTR analysis of 127 B-ALL patients aged 40-75 receiving tisagenlecleucel. Patients ≥55 (n=48) had similar CR rates to younger adults (81% vs 85%) but higher 1-year NRM (14% vs 6%, p=0.03). Prolonged B-cell aplasia led to more infectious complications in older patients. Median OS was 18.2 months for elderly vs 25.6 months for younger adults, partly driven by reduced salvage options after CAR-T failure in the older cohort.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "tisagenlecleucel",
    "indication": "B-ALL",
    "population_size": 127,
    "median_followup_months": 22.4,
    "primary_endpoint": "CR rate",
    "outcome_value": "81% in ≥55 years",
    "setting": "both",
    "special_population": "elderly ≥65"
  },
  {
    "id": "rwe-bridging-impact-011",
    "text_summary": "Retrospective analysis of 523 LBCL patients comparing outcomes with bridging therapy (n=341) vs no bridging (n=182) prior to axicabtagene ciloleucel. Bridging was associated with lower CR rate (48% vs 61%, p=0.004) and shorter median PFS (5.2 vs 11.8 months). However, patients receiving bridging had higher disease burden at referral. After propensity score matching, bridging itself was not an independent predictor of PFS, suggesting disease biology drives outcomes rather than bridging per se.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "axicabtagene ciloleucel",
    "indication": "LBCL",
    "population_size": 523,
    "median_followup_months": 18.7,
    "primary_endpoint": "PFS",
    "outcome_value": "5.2 months (bridging) vs 11.8 months (no bridging)",
    "setting": "academic",
    "special_population": "bridging therapy"
  },
  {
    "id": "rwe-bridging-chemo-012",
    "text_summary": "Analysis of bridging therapy regimens in 289 patients awaiting CAR-T. Chemotherapy bridging (R-GemOx, polatuzumab-BR) was used in 61%, radiation in 22%, and steroids-only in 17%. Radiation bridging was associated with best outcomes (ORR 74%) likely due to selection of localized disease. Chemotherapy bridging with polatuzumab-BR yielded 52% ORR post-CAR-T. Progressive disease during bridging (31% of patients) was the strongest negative predictor of CAR-T response (ORR 38% vs 71%).",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 289,
    "median_followup_months": 14.3,
    "primary_endpoint": "ORR",
    "outcome_value": "71% (responding to bridge) vs 38% (progressing)",
    "setting": "academic",
    "special_population": "bridging therapy"
  },
  {
    "id": "rwe-bridging-none-013",
    "text_summary": "Single-center study of 94 LBCL patients who received no bridging therapy before CAR-T, representing 28% of their total referrals. These patients had lower tumor burden (median SPD 18 vs 42 cm2) and better ECOG performance status. ORR was 79% with 62% CR. Median PFS was 14.7 months. The no-bridging group had lower grade 3+ CRS (6% vs 14%) and shorter hospital stays (median 10 vs 16 days), consistent with lower baseline inflammatory burden.",
    "study_type": "retrospective",
    "data_source": "institutional",
    "product": "lisocabtagene maraleucel",
    "indication": "LBCL",
    "population_size": 94,
    "median_followup_months": 16.1,
    "primary_endpoint": "ORR",
    "outcome_value": "79%",
    "setting": "academic",
    "special_population": "bridging therapy"
  },
  {
    "id": "rwe-longterm-axi-014",
    "text_summary": "Five-year follow-up of 267 patients treated with axicabtagene ciloleucel for LBCL in the commercial setting (2018-2019 infusions). Five-year OS was 40.2% and 5-year PFS was 31.8%. Among patients in CR at 12 months (n=128), the 5-year PFS was 72%, indicating durable remission in early responders. Late relapses beyond 24 months were rare (4.7%). Late-onset toxicities included prolonged hypogammaglobulinemia (63%) requiring IVIG and persistent cytopenias at 1 year (12%).",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "axicabtagene ciloleucel",
    "indication": "LBCL",
    "population_size": 267,
    "median_followup_months": 60.3,
    "primary_endpoint": "OS",
    "outcome_value": "40.2% at 5 years",
    "setting": "academic",
    "special_population": ""
  },
  {
    "id": "rwe-longterm-tisa-015",
    "text_summary": "Three-year outcomes from 184 patients treated with tisagenlecleucel for B-ALL (pediatric and young adult). Three-year OS was 56% and event-free survival was 44%. Among patients achieving MRD-negative CR (76%), 3-year EFS was 58%. Loss of B-cell aplasia (BCA) preceded relapse in 72% of cases. Late neurotoxicity was not observed. Cumulative incidence of subsequent allogeneic SCT was 18% at 3 years, mostly for patients with early loss of BCA.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "tisagenlecleucel",
    "indication": "B-ALL",
    "population_size": 184,
    "median_followup_months": 38.6,
    "primary_endpoint": "OS",
    "outcome_value": "56% at 3 years",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-longterm-cilta-016",
    "text_summary": "Three-year real-world follow-up of 309 multiple myeloma patients receiving ciltacabtagene autoleucel. Median PFS was 21.8 months with 3-year PFS of 34%. Three-year OS was 58%. Among patients achieving sCR (41%), 3-year PFS was 62%. Late movement and neurocognitive toxicity (MNT) occurred in 5.2%, lower than initial clinical trial reports (7%), possibly due to improved recognition and early intervention. MRD negativity at 10^-5 was the strongest predictor of durable response.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "ciltacabtagene autoleucel",
    "indication": "Multiple Myeloma",
    "population_size": 309,
    "median_followup_months": 36.4,
    "primary_endpoint": "PFS",
    "outcome_value": "34% at 3 years",
    "setting": "academic",
    "special_population": ""
  },
  {
    "id": "rwe-resource-icu-017",
    "text_summary": "Resource utilization analysis of 618 commercial CAR-T infusions across 8 centers. ICU admission rate was 29%, with median ICU stay of 3 days (IQR 2-6). ICU admission was driven by CRS (68%), ICANS (21%), or both (11%). Patients receiving axicabtagene ciloleucel had higher ICU rates (35%) vs lisocabtagene maraleucel (18%). Early tocilizumab protocols reduced ICU transfers by 38%. Median total hospital length of stay was 16 days (IQR 11-24) for inpatient CAR-T administration.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 618,
    "median_followup_months": 6.0,
    "primary_endpoint": "ICU admission rate",
    "outcome_value": "29%",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-resource-readmit-018",
    "text_summary": "Insurance claims analysis of 30-day and 90-day readmission rates following CAR-T therapy. Among 1842 patients, 30-day readmission was 34% and 90-day readmission was 48%. Most common readmission causes: infection (31%), cytopenias/febrile neutropenia (24%), delayed neurotoxicity (12%), and disease progression (9%). Median cost of index hospitalization was $468,000 and 90-day total cost including readmissions was $612,000. Outpatient CAR-T administration (7% of cohort) had 22% lower 30-day readmission.",
    "study_type": "claims",
    "data_source": "insurance_claims",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 1842,
    "median_followup_months": 3.0,
    "primary_endpoint": "30-day readmission rate",
    "outcome_value": "34%",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-resource-cost-019",
    "text_summary": "EHR-linked claims analysis of total cost of care for CAR-T therapy in 743 LBCL patients over 1 year. Median 1-year total cost was $587,000 including product acquisition ($373,500), hospitalization ($124,000), and outpatient follow-up ($89,500). Patients with grade 3+ CRS/ICANS had $218,000 higher costs. Patients in CR at 6 months had lower 6-12 month costs ($12,400) vs non-responders ($87,600). Cost-effectiveness improved when used in second-line vs third-line due to better outcomes and shorter prior treatment costs.",
    "study_type": "ehr_analysis",
    "data_source": "insurance_claims",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 743,
    "median_followup_months": 12.0,
    "primary_endpoint": "total cost of care",
    "outcome_value": "$587,000 median 1-year",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-disparity-access-020",
    "text_summary": "SEER-Medicare linked analysis of 4287 LBCL patients eligible for CAR-T (2018-2023). Only 11.3% received CAR-T. Black patients were 42% less likely to receive CAR-T than White patients (OR 0.58, 95% CI 0.44-0.76) after adjusting for age, comorbidities, and insurance. Hispanic patients had 35% lower access (OR 0.65). Geographic distance to certified center >50 miles reduced access by 51%. Rural patients had the lowest CAR-T utilization (5.2%) compared to urban (13.8%).",
    "study_type": "ehr_analysis",
    "data_source": "SEER",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 4287,
    "median_followup_months": 24.0,
    "primary_endpoint": "CAR-T utilization rate",
    "outcome_value": "11.3% overall",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-disparity-outcomes-021",
    "text_summary": "Multi-center analysis of CAR-T outcomes by race/ethnicity in 672 patients who received commercial CAR-T for LBCL. ORR was similar across groups: White 72%, Black 68%, Hispanic 70% (p=0.51). However, Black patients had higher NRM at 1 year (9.1% vs 4.8%, p=0.04) and lower 2-year OS (41% vs 52%, p=0.03). Differences were partly explained by higher comorbidity burden, longer time from diagnosis to CAR-T (median 18.2 vs 13.4 months), and more advanced disease at referral in Black patients.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 672,
    "median_followup_months": 20.3,
    "primary_endpoint": "OS",
    "outcome_value": "52% White vs 41% Black at 2 years",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-prior-allo-022",
    "text_summary": "Retrospective analysis of 156 patients who received CAR-T after prior allogeneic stem cell transplant. ORR was 64% with 42% CR, numerically lower than non-allo patients (73% ORR). Graft-versus-host disease (GVHD) flare occurred in 9% of patients, all with prior chronic GVHD history. Grade 3+ CRS rates were similar to non-allo patients. Median PFS was 5.4 months. Donor-derived CAR-T cells (from the allograft) were detected in 78% of products, raising questions about the functional impact of donor vs recipient T cells.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 156,
    "median_followup_months": 15.2,
    "primary_endpoint": "ORR",
    "outcome_value": "64%",
    "setting": "academic",
    "special_population": "prior allo-SCT"
  },
  {
    "id": "rwe-prior-allo-ball-023",
    "text_summary": "CIBMTR analysis of 89 pediatric/young adult B-ALL patients receiving tisagenlecleucel after prior allogeneic SCT. CR rate was 82%, comparable to non-allo patients (88%). GVHD reactivation occurred in 6.7%, all manageable with steroids. One-year EFS was 42% and OS was 61%. Importantly, prior allo-SCT was not a negative prognostic factor for CAR-T response in B-ALL. Manufacturing success rate was 97%, with products containing predominantly donor-derived T cells.",
    "study_type": "registry",
    "data_source": "CIBMTR",
    "product": "tisagenlecleucel",
    "indication": "B-ALL",
    "population_size": 89,
    "median_followup_months": 18.9,
    "primary_endpoint": "CR rate",
    "outcome_value": "82%",
    "setting": "both",
    "special_population": "prior allo-SCT"
  },
  {
    "id": "rwe-cns-safety-024",
    "text_summary": "Multi-center retrospective of 83 LBCL patients with active or prior CNS involvement who received commercial CAR-T. CNS response rate was 56% with 38% CNS CR. Grade 3+ ICANS was higher than non-CNS cohorts (28% vs 12%), with 4 patients requiring prolonged ICU care. No CAR-T-related deaths in the CNS group. Median PFS was 4.2 months and median OS was 9.7 months. Active CNS disease at infusion (n=47) had worse outcomes than prior CNS disease in remission (n=36), with PFS of 2.8 vs 7.1 months.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "axicabtagene ciloleucel",
    "indication": "LBCL",
    "population_size": 83,
    "median_followup_months": 13.6,
    "primary_endpoint": "CNS response rate",
    "outcome_value": "56%",
    "setting": "academic",
    "special_population": "CNS involvement"
  },
  {
    "id": "rwe-cns-ball-025",
    "text_summary": "Analysis of 52 B-ALL patients with CNS-2 or CNS-3 status who received tisagenlecleucel. CNS clearance was achieved in 71% of patients. Grade 3+ ICANS occurred in 23% but was reversible in all cases. Median EFS was 8.4 months. Patients with isolated CNS relapse (n=14) had better outcomes (EFS 14.2 months) than combined medullary and CNS disease (n=38, EFS 6.1 months). CAR-T cell detection in CSF correlated with CNS response, supporting active trafficking across the blood-brain barrier.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "tisagenlecleucel",
    "indication": "B-ALL",
    "population_size": 52,
    "median_followup_months": 16.8,
    "primary_endpoint": "CNS clearance rate",
    "outcome_value": "71%",
    "setting": "academic",
    "special_population": "CNS involvement"
  },
  {
    "id": "rwe-retreat-lbcl-026",
    "text_summary": "Multi-center experience with second CAR-T infusion in 74 LBCL patients who relapsed after initial CAR-T. The same product was used in 41 patients and a different product in 33. ORR to second infusion was 34% (same product 24%, different product 47%, p=0.03). Median duration of response was 4.1 months. Grade 3+ CRS was 8% on retreatment. CD19 expression was confirmed positive in 81% of retreated patients. Loss of CD19 was the primary mechanism of resistance in non-responders to both first and second infusion.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 74,
    "median_followup_months": 11.2,
    "primary_endpoint": "ORR",
    "outcome_value": "34%",
    "setting": "academic",
    "special_population": ""
  },
  {
    "id": "rwe-retreat-ball-027",
    "text_summary": "Analysis of 41 B-ALL patients who received a second CAR-T infusion (tisagenlecleucel re-infusion n=23, humanized CD19 CAR n=18) after relapse with CD19-positive disease. CR rate was 46% overall (39% same product, 56% different construct). Median EFS from second infusion was 5.8 months. Anti-CAR antibodies (HAMA) were detected in 35% of re-infused patients and correlated with poor expansion and lower response rate. Lymphodepletion with fludarabine/cyclophosphamide before second infusion improved outcomes.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "tisagenlecleucel",
    "indication": "B-ALL",
    "population_size": 41,
    "median_followup_months": 14.5,
    "primary_endpoint": "CR rate",
    "outcome_value": "46%",
    "setting": "academic",
    "special_population": ""
  },
  {
    "id": "rwe-timing-early-028",
    "text_summary": "Retrospective analysis of 438 LBCL patients examining impact of time from last relapse to CAR-T infusion. Patients infused within 60 days of progression (n=186) had ORR 78% vs 64% for those infused >90 days after progression (n=252, p=0.001). Median OS was 28.4 months vs 15.1 months respectively. Shorter time to infusion correlated with lower tumor burden (median SPD 22 vs 48 cm2) and better performance status. Vein-to-vein time >45 days was associated with significantly worse outcomes.",
    "study_type": "retrospective",
    "data_source": "multi_center",
    "product": "axicabtagene ciloleucel",
    "indication": "LBCL",
    "population_size": 438,
    "median_followup_months": 22.8,
    "primary_endpoint": "OS",
    "outcome_value": "28.4 months (early) vs 15.1 months (late)",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-timing-2l-vs-3l-029",
    "text_summary": "Meta-analysis of real-world studies comparing second-line vs third-line or later CAR-T in LBCL, incorporating data from 2847 patients across 14 studies post-ZUMA-7/TRANSFORM/BELINDA era. Second-line CAR-T (n=1123) showed ORR 79% with 65% CR and 2-year PFS of 51%, significantly superior to third-line (n=1724) with ORR 68%, 49% CR, and 2-year PFS 33% (p<0.001). Grade 3+ CRS was similar (10% vs 12%). Earlier CAR-T use was associated with 37% reduction in overall mortality (HR 0.63, 95% CI 0.54-0.74).",
    "study_type": "meta_analysis",
    "data_source": "multi_center",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 2847,
    "median_followup_months": 18.4,
    "primary_endpoint": "PFS",
    "outcome_value": "51% at 2 years (2L) vs 33% (3L+)",
    "setting": "both",
    "special_population": ""
  },
  {
    "id": "rwe-europe-descart-030",
    "text_summary": "DESCAR-T French national registry analysis of 892 patients receiving commercial CAR-T for LBCL (2019-2023). ORR was 66% with 47% CR. Median PFS was 6.1 months and median OS was 16.8 months. Grade 3+ CRS occurred in 7% and grade 3+ ICANS in 10%. Outcomes were similar to US CIBMTR data despite different healthcare system structures. French centers had slightly longer vein-to-vein times (median 38 days) due to centralized manufacturing logistics. EBMT cross-validation confirmed concordant results across European registries.",
    "study_type": "registry",
    "data_source": "DESCAR-T",
    "product": "mixed",
    "indication": "LBCL",
    "population_size": 892,
    "median_followup_months": 19.6,
    "primary_endpoint": "ORR",
    "outcome_value": "66%",
    "setting": "multicenter",
    "special_population": ""
  }
]
